Insider Buying: Sensus Healthcare (NASDAQ:SRTS) Director Acquires $11,250.00 in Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta acquired 2,500 shares of the stock in a transaction dated Thursday, November 13th. The stock was acquired at an average price of $4.50 per share, for a total transaction of $11,250.00. Following the completion of the acquisition, the director directly owned 133,113 shares of the company’s stock, valued at $599,008.50. The trade was a 1.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Eric Sachetta also recently made the following trade(s):

• On Friday, November 21st, Eric Sachetta bought 7,000 shares of Sensus Healthcare stock. The shares were acquired at an average price of $3.93 per share, with a total value of $27,510.00.

Sensus Healthcare Trading Up 2.3%

Sensus Healthcare stock opened at $4.02 on Friday. Sensus Healthcare, Inc. has a 1-year low of $3.03 and a 1-year high of $9.33. The company has a fifty day simple moving average of $3.47 and a 200 day simple moving average of $4.06. The company has a market cap of $66.03 million, a P/E ratio of -67.00 and a beta of 1.38.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.06. Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.58%. The firm had revenue of $6.88 million for the quarter, compared to analysts’ expectations of $6.31 million. On average, equities research analysts forecast that Sensus Healthcare, Inc. will post 0.32 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on the company. HC Wainwright reduced their price target on Sensus Healthcare from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, August 12th. Zacks Research raised Sensus Healthcare from a “strong sell” rating to a “hold” rating in a report on Wednesday, October 22nd. Lake Street Capital decreased their target price on shares of Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a research note on Saturday. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Sensus Healthcare has an average rating of “Hold” and a consensus price target of $8.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SRTS. Kingstone Capital Partners Texas LLC bought a new stake in Sensus Healthcare in the 2nd quarter valued at $3,170,000. Divisadero Street Capital Management LP increased its holdings in shares of Sensus Healthcare by 459.4% in the second quarter. Divisadero Street Capital Management LP now owns 324,673 shares of the company’s stock valued at $1,539,000 after purchasing an additional 266,635 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Sensus Healthcare by 35.3% in the first quarter. Acadian Asset Management LLC now owns 470,713 shares of the company’s stock valued at $2,225,000 after purchasing an additional 122,746 shares during the period. Pacific Ridge Capital Partners LLC raised its position in shares of Sensus Healthcare by 26.1% in the third quarter. Pacific Ridge Capital Partners LLC now owns 573,389 shares of the company’s stock valued at $1,800,000 after purchasing an additional 118,628 shares during the period. Finally, Meros Investment Management LP acquired a new stake in shares of Sensus Healthcare during the 1st quarter worth about $419,000. 25.30% of the stock is owned by institutional investors and hedge funds.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.